Affymax(R) Announces Phase 3 Development Plan for Hematide(TM) (Business Wire via Yahoo! Finance)
PALO ALTO, Calif.----Affymax, Inc. today announced that it plans to initiate Phase 3 clinical studies with Hematide in chronic renal failure patients following recent discussions with the United States Food and Drug Administration on the design of the Phase 3 clinical trial program.

Pipex Pharmaceuticals' Oral TRIMESTA Initiates Dosing in Phase II/III Clinical Trial for Multiple Sclerosis (Marketwire via Yahoo! Finance)
Pipex Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has initiated patient dosing of TRIMESTA, its proprietary therapy for multiple sclerosis, in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS. This clinical ...